BIOCRYST PHARMACEUTICALS INC (58)

Browse by Contract Category

Contracts

the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO(berotralstat), BCX9930,... (Filed With SEC on May 9, 2022)
EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104 (Filed With SEC on February 28, 2022)
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on November 4, 2021)
BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan (as amended and restated as of April 1, 2021) (Filed With SEC on May 26, 2021)
the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO(berotralstat), BCX9930,... (Filed With SEC on May 9, 2022)
EX-10.72 EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104 (Filed With SEC on February 28, 2022)
EX-10.14 EX-10.72 EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104 (Filed With SEC on February 28, 2022)
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on November 4, 2021)
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on November 4, 2021)
(Filed With SEC on November 4, 2021)
Amendment, dated August 27, 2021, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services (Filed With SEC on September 1, 2021)
(Filed With SEC on August 9, 2021)
(Filed With SEC on August 9, 2021)
(Filed With SEC on August 9, 2021)
(Filed With SEC on August 9, 2021)
Separation Agreement and Release, dated August 8, 2021, by and between BioCryst Pharmaceuticals, Inc. and Megan Sniecinski (Filed With SEC on August 9, 2021)
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 1, 2021) (Filed With SEC on May 26, 2021)
BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD (Filed With SEC on May 7, 2021)
(Filed With SEC on May 7, 2021)
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)
BioCryst Pharmaceuticals, Inc. Annual Incentive Plan, effective as of December 16, 2020 (Filed With SEC on December 17, 2020)
(Filed With SEC on November 6, 2020)
THIRD aMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (Filed With SEC on November 6, 2020)
(Filed With SEC on November 6, 2020)
(Filed With SEC on November 6, 2020)
(Filed With SEC on November 6, 2020)
(Filed With SEC on November 6, 2020)
Amendment, dated August 31, 2020, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services (Filed With SEC on September 3, 2020)
(Filed With SEC on August 10, 2020)
Underwriting Agreement, dated May 27, 2020, by and among BioCryst Pharmaceuticals, Inc. and J.P. Morgan Securities LLC and Piper Sandler & Co., as representatives of the... (Filed With SEC on June 1, 2020)
Form of Warrant to Purchase Common Stock, dated June 1, 2020 (Filed With SEC on June 1, 2020)
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of March 19, 2020) (Filed With SEC on May 13, 2020)
BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan (as amended and restated as of March 19, 2020) (Filed With SEC on May 13, 2020)
Cash and cash equivalents (Filed With SEC on May 11, 2020)
Cash and cash equivalents (Filed With SEC on May 11, 2020)
Drug/Drug Candidate (Filed With SEC on March 13, 2020)
Drug/Drug Candidate (Filed With SEC on March 13, 2020)
Description of Common Stock (Filed With SEC on March 13, 2020)
Form of Warrant to Purchase Common Stock, dated November 21, 2019 (Filed With SEC on November 21, 2019)
Securities Purchase Agreement, dated November 19, 2019, among BioCryst Pharmaceuticals, Inc., Baker Brothers Life Sciences, L.P. and 667, L.P (Filed With SEC on November 20, 2019)
Underwriting Agreement, dated November 13, 2019, by and between BioCryst Pharmaceuticals, Inc. and J.P. Morgan Securities LLC, as representative of the underwriters named in... (Filed With SEC on November 18, 2019)
Cash and cash equivalents (Filed With SEC on November 8, 2019)
Cash and cash equivalents (Filed With SEC on November 8, 2019)
Amendment dated as of September 23, 2019 to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services (Filed With SEC on September 26, 2019)
Cash and cash equivalents (Filed With SEC on August 8, 2019)
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as Amended and Restated April 12, 2019) (Filed With SEC on June 4, 2019)
Cash and cash equivalents (Filed With SEC on May 9, 2019)